Mirum Pharmaceuticals (MIRM) Other financing activities (2020 - 2026)

Mirum Pharmaceuticals' Other financing activities history runs 7 years deep, the most recent figure standing at $259.9 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 3987.88% year-over-year to $259.9 million in Q1 2026; TTM through Mar 2026 was $253.6 million, a 1009.65% increase from a year earlier, with the FY2024 full-year figure at $17.7 million, down 91.25% from the prior year.
• Other financing activities climbed to $259.9 million in Q1 2026 per MIRM's latest filing, from -$31.1 million in the prior quarter.
• Across five years, Other financing activities topped out at $259.9 million in Q1 2026 and bottomed at -$31.1 million in Q4 2025.
• The 5-year median for Other financing activities is $5.3 million (2024), against an average of $27.9 million.
• Across the five-year window, Other financing activities slumped 683.2% in 2025 and soared 3987.88% in 2026, its largest moves.
• Year by year, Other financing activities stood at -$2.0 million in 2022, then surged by 92.15% to -$159000.0 in 2023, then surged by 3458.49% to $5.3 million in 2024, then slumped by 683.2% to -$31.1 million in 2025, then jumped by 934.69% to $259.9 million in 2026.
• Per Business Quant, the three latest MIRM Other financing activities figures stand at $259.9 million (Q1 2026), -$31.1 million (Q4 2025), and $16.1 million (Q3 2025).